Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on December 15, 2008, regarding events occurring on December 9, 2008. The filing addresses the Compensation Committee's approval of 2009 base salaries and stock option awards for executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes Versus Prior Period
- Salary Adjustments: In response to broader market conditions and to conserve cash, the Compensation Committee decided that no officers would receive merit increases for 2009, with one exception.
- Exception: Barry E. Greene, President and Chief Operating Officer, received a base salary increase from $350,000 in 2008 to $390,000 in 2009 to align with industry peer group compensation.
- Other Officers: Base salaries for CEO John M. Maraganore, SVP John A. Schmidt, Jr., and VP Patricia L. Allen remained consistent with their 2008 levels.
- Equity Awards: Option awards were granted to all listed executive officers in recognition of 2008 performance. The exercise price for these options is $21.35 per share.
Guidance, Outlook, and Management Commentary
Management acknowledged the Company's accomplishments during 2008 but emphasized the need to conserve cash due to broader market conditions. The decision to freeze merit increases for most officers reflects this liquidity preservation strategy. The filing does not contain forward-looking financial guidance, risk factors, or contingencies beyond the compensation context.
Important Facts for Investor Verification
- Verify the total number of shares underlying the new option awards (153,320 for CEO, 90,000 for COO, 31,663 for CFO, and 15,000 for CSO).
- Confirm the vesting schedule: 25% on the first anniversary of the grant date, followed by 6.25% every three months thereafter until the fourth anniversary.
- Note that Dr. Schmidt received a pro-rated award as he joined the Company in October 2008.
- Review the Company's cash position in subsequent filings to assess the impact of the "conserve cash" strategy mentioned in the report.